Prognostic Value of Different Patterns of Squamous Cell Carcinoma Antigen Level for the Recurrent Cervical Cancer.
- Author:
Bae Kwon JEONG
1
;
Seung Jae HUH
;
Doo Ho CHOI
;
Won PARK
;
Duk Soo BAE
;
Byoung Gie KIM
Author Information
1. Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. doho.choi@samsung.com
- Publication Type:Original Article
- Keywords:
Uterine cervical neoplasms;
Squamous cell carcinoma-related antigen;
Biological tumor markers
- MeSH:
Antigens, Neoplasm;
Carcinoma, Squamous Cell;
Disease-Free Survival;
Follow-Up Studies;
Humans;
Multivariate Analysis;
Prognosis;
Recurrence;
Serpins;
Survival Rate;
Biomarkers, Tumor;
Uterine Cervical Neoplasms
- From:Cancer Research and Treatment
2013;45(1):48-54
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: In some unusual cases, in patients with cervical cancer, an elevation of squamous cell carcinoma antigen (SCC-Ag) was not observed at diagnosis but was observed on recurrence, or vice versa. The objective of this study was to identify patient-, disease-, and treatment-related factors associated with this unusual level of SCC-Ag, and to determine whether SCC-Ag is a useful tumor marker in such patients. MATERIALS AND METHODS: Among 129 patients with recurrence, 14 who showed a normal SCC-Ag level at diagnosis but an elevated level at recurrence were classified as group I; 22 patients with an elevated SCC-Ag level at diagnosis but not at recurrence were classified as group II; and 76 patients with an elevated SCC-Ag level at both diagnosis and recurrence were classified as group III. RESULTS: In univariate analysis, unusual SCC-Ag showed statistically significant relationships with pathology and biochemical response to treatment. However, in the multivariate analysis, none of the clinicopathologic factors showed a statistical relationship with unusual levels of SCC-Ag. The 5-year disease-free survival rates for groups I, II, and III were 7.1%, 9.1%, and 0% (p=0.418), and the 5-year overall survival rates were 34.3%, 58.4%, and 33.3% (p=0.142), respectively. CONCLUSION: The value of SCC-Ag has been confirmed in all patients; thus, check of SCC-Ag level at follow-up should be considered. Although no statistically significant differences were observed among the groups, we conclude that patients with a high initial SCC-Ag and elevated SCC-Ag at relapse have poor prognosis due to high SCC-Ag level.
